Barzolvolimab Shows Sustained Efficacy, Disease Modification in Phase 2 Urticaria Data
CLDX has more than doubled off its 52-week low of $14.4.
Summary
Celldex Therapeutics presented additional positive Phase 2 data for its lead asset, barzolvolimab, in Chronic Spontaneous Urticaria (CSU), Cold Urticaria (ColdU), and Symptomatic Dermographism (SD) at the AAAAI 2026 meeting. The data highlighted sustained off-treatment efficacy in CSU patients, with up to 41% achieving complete response seven months after their last dose, suggesting potential disease modification. This is a significant finding, as it implies a lasting impact beyond active treatment. This positive update follows the company's recent announcement of completed Phase 3 enrollment for barzolvolimab in CSU, as noted in the recent 10-K filing. The new data further strengthens barzolvolimab's profile as a potential 'first-in-class and best-in-disease' treatment, significantly de-risking the asset and enhancing its commercial prospects. Investors will now closely monitor the progress and eventual readout of the ongoing Phase 3 CSU trials.
At the time of this announcement, CLDX was trading at $29.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $14.40 to $31.31. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.